BridgeBio Pharma Total Non-Operating Income/Expense 2018-2024 | BBIO

BridgeBio Pharma total non-operating income/expense from 2018 to 2024. Total non-operating income/expense can be defined as the sum of all non-operating expenses for the given industry.
BridgeBio Pharma Annual Total Non-Operating Income/Expense
(Millions of US $)
2023 $-46
2022 $28
2021 $-10
2020 $-31
2019 $-22
2018 $14
2017 $0
BridgeBio Pharma Quarterly Total Non-Operating Income/Expense
(Millions of US $)
2024-06-30 $100
2024-03-31 $-37
2023-12-31 $7
2023-09-30 $-22
2023-06-30 $-15
2023-03-31 $-17
2022-12-31 $-11
2022-09-30 $-11
2022-06-30 $78
2022-03-31 $-28
2021-12-31 $13
2021-09-30 $-12
2021-06-30 $-8
2021-03-31 $-4
2020-12-31 $-8
2020-09-30 $-10
2020-06-30 $-12
2020-03-31 $-2
2019-12-31 $-6
2019-09-30 $-6
2019-06-30 $-5
2019-03-31 $-6
2018-12-31
2018-09-30 $-1
2017-12-31
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $4.911B $0.009B
BridgeBio Pharma Inc. discovers, develops and innovates drugs for genetic diseases. The Company's product platform consists of Mendelian, Oncology and Gene therapy. Its product pipeline includes BBP-265, BBP-831, BBP-631 and BBP-454 which are in clinical stage. BridgeBio Pharma Inc. is based in CA, United States.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $19.679B 6.46
Dr Reddy's Laboratories (RDY) India $12.521B 23.96
Bausch Health Cos (BHC) Canada $3.439B 2.49
Amphastar Pharmaceuticals (AMPH) United States $2.335B 14.04
Supernus Pharmaceuticals (SUPN) United States $2.022B 27.53
Taysha Gene Therapies (TSHA) United States $0.334B 54.33
Personalis (PSNL) United States $0.261B 0.00
Assembly Biosciences (ASMB) United States $0.104B 0.00
Sol-Gel Technologies (SLGL) Israel $0.015B 0.00
Evoke Pharma (EVOK) United States $0.004B 0.00
Teligent (TLGT) United States $0.000B 0.00